Mirati Therapeutics has selected ZoBio to provide fragment-based screening, biophysical compound characterization and structural biology for several oncology targets. In this arrangement, ZoBio screens…
Axxam and ZoBio Form a Strategic Alliance Integrating their Drug Discovery Services Platforms
MILAN, IT, AND LEIDEN, NL
Axxam and ZoBio have initiated a strategic alliance to provide a combination of integrated discovery services spanning all phases from gene to fully optimized leads.
This alliance provides access to a synergistic, industry-leading…
Gotham Therapeutics and ZoBio Achieve Significant Milestone in Epitranscriptomic Drug Discovery Collaboration
NEW YORK, NY, USA AND LEIDEN, NL
Gotham Therapeutics has selected ZoBio to initiate a collaboration on the development of small molecules targeting epitranscriptomic targets. This collaboration has now resulted in several lead candidates for the METTL3/METTL14 complex…